Press Releases

NEW YORK, NY, June 15, 2026 – On Wednesday, June 3, the Lustgarten Foundation welcomed supporters, researchers, physicians, industry leaders, and philanthropic partners to its annual Inspiring Hope Gala at […]

For years, pancreatic cancer has been considered immune to immunotherapy. Its tumors were “cold”—invisible to the body’s natural defenses and resistant to treatments that worked against other cancers. Patients had […]

For decades, pancreatic cancer has remained one of the most difficult cancers to treat. Too often diagnosed late and resistant to many standard therapies, it has long demanded new thinking, […]

UPDATE (5/12/2026): Following last week’s announcement of expanded access for daraxonrasib in pancreatic cancer, Revolution Medicines has now shared additional information and guidelines for physicians and patients interested in the […]

The Lustgarten Foundation’s annual International Women’s Day symposium, The Power of Persistence: Women Transforming Cancer Research and Care, highlights women’s critical role in advancing innovation in the fight against cancer. Co-chaired […]

We were disappointed to learn that the Galleri multi-cancer early detection (MCED) test, developed by GRAIL, did not meet the primary endpoint in its large randomized trial conducted in partnership […]

While cancer mortality rates in the United States have steadily declined over recent decades, a group of recalcitrant cancers remains stubbornly lethal. For diseases like pancreatic, ovarian, and upper GI […]

WHY EARLY DETECTION IN PANCREATIC CANCER CAN’T WAIT For decades, pancreatic cancer has been defined by late diagnosis and limited options. The disease often progresses silently and aggressively, with symptoms […]